Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 4

1(16.7%)

N/A

1(16.7%)

6Total

Phase 3(4)

Phase 4(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02913521Phase 3Completed

Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%

Role: lead

NCT02624843Phase 3Completed

Bioequivalence Study for Benzyl Alcohol Lotion 5%.

Role: lead

NCT03522441Phase 3Completed

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

Role: lead

NCT02423148Not ApplicableWithdrawn

Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer

Role: collaborator

NCT02758327Phase 4Completed

Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops

Role: collaborator

NCT01561521Phase 3Completed

An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis

Role: lead

All 6 trials loaded